GEN Exclusives

More »

GEN News Highlights

More »
Mar 20, 2007

GenVec Signs CRADA with the NIAID to Develop RSV Vaccines

  • GenVec signed a CRADA with the NIAID to develop adenovector-based vaccines for the prevention and treatment of respiratory syncytial virus (RSV).

    The collaborative research will combine NIAID's scientific and clinical expertise in RSV with GenVec's experience in development of adenovector-based vaccines and manufacturing process.

    In addition to the RSV collaboration, GenVec is working with the NIAID on the clinical development of HIV and influenza vaccines. "Data emerging from the clinical trials of our HIV vaccine candidate indicates that GenVec's adenovector technology induces both antibodies and cellular immune responses," notes Rick King, GenVec's senior vp of research. "This has the potential to be highly effective in preventing RSV-induced disease."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?